In addition to the mentioned ongoing phase 2 study examining the effect of E2-triggered ERβ activation in TNBC, further in vivo studies and clinical trials are necessary to elucidate the eligibility of ERRs or GPER-1 as targets for endocrine treatment of this cancer entity. Here, GPER1 is linked to cancer.